Rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor that increases dopaminergic neurotransmission and is currently used for motor symptoms of PD, has been shown to have beneficial effects on specific aspects of attention and executive function in pwPD without dementia in another randomized, placebo-controlled clinical trial (NCT00696215) [67]. This evidence concerns the gene MAOB and dementia.